Related Experiment Video
Updated: Jun 4, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel
Huiwen Ke1, Wenchao Chen2, Qian Zhang3
1Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Introduction:
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder mainly affecting the young and female with limited therapeutic options, necessitating the identification of novel drug targets. This study aimed to identify and prioritize new, genetically validated drug targets for IBS by leveraging large-scale human genetic data.
Methods:
We conducted a systematic, druggable genome-wide Mendelian randomization (MR) analysis to evaluate the causal effects of 5,642 potential druggable protein-coding genes on IBS risk. The analysis integrated summary statistics from the largest available IBS genome-wide association study (GWAS), including 53,400 cases and 433,201 controls, with comprehensive blood expression quantitative trait loci (eQTL) data. Significant findings were further validated using colocalization analysis. A phenome-wide association study (PheWAS) was performed to assess the potential for on-target adverse effects. Finally, potential therapeutic compounds were predicted using the Drug Signatures Database (DSigDB) and molecular docking.
Results:
The MR analysis identified eight genes with potential causal associations with IBS. Following rigorous validation with colocalization analysis, EP300 and P2RY14 emerged as the most promising candidate targets. Genetically predicted higher expression of both EP300 (OR: 1.128, 95% CI: 1.079-1.180) and P2RY14 (OR: 1.118, 95% CI: 1.067-1.172) was suggestively causally associated with an increased risk of IBS. The PheWAS analysis indicated that EP300 and P2RY14 did not show genome-wide significant associations with any other phenotypes. Additionally, molecular docking predicted that existing compounds, such as captopril and menadione, could effectively bind to the EP300 protein.
Conclusion:
Our study provides genetic evidence establishing EP300 and P2RY14 as promising drug targets for the treatment of IBS, laying a foundation for future drug development and repurposing efforts.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:23Irritable Bowel Syndrome
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:21Drugs for Treatment of Constipation-Predominant IBS